AstraZeneca said a lab-study of its COVID-19 antibody cocktail, Evusheld, found that the treatment retained neutralising activity against the Omicron coronavirus variant, showing promise for wider use of the therapy.
The study was conducted by independent investigators of the U.S. Food and Drug Administration, the company said, adding that more analyses of Evusheld against Omicron are being conducted by AstraZeneca and third-parties, with data expected “very soon”.
One of our Supreme Court judges made an important if startling point when giving a lecture abroad. A legal website...
Read more
The Uttarakhand government has been struggling to work with only 76 IAS officers in the state, even though it has...
Read more
Austria and New Zealand may be far apart geographically, but we are connected by shared values and principles. Particularly relevant...
Read more
French politics is thrown into turmoil after President Emmanuel Macron lost control of the National Assembly in legislative elections in which...
Read more
